Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Shares Outstanding (2016 - 2025)

Ani Pharmaceuticals' Shares Outstanding history spans 10 years, with the latest figure at $17.6 million for Q2 2022.

  • For Q2 2022, Shares Outstanding rose 21857.5% year-over-year to $17.6 million; the TTM value through Jun 2022 reached $17.6 million, up 21857.5%, while the annual FY2021 figure was $16.9 million, 22153.95% up from the prior year.
  • Shares Outstanding for Q2 2022 was $17.6 million at Ani Pharmaceuticals, up from $123000.0 in the prior quarter.
  • Across five years, Shares Outstanding topped out at $17.6 million in Q2 2022 and bottomed at $11730.0 in Q1 2018.
  • The 5-year median for Shares Outstanding is $103000.0 (2021), against an average of $6.0 million.
  • The largest YoY upside for Shares Outstanding was 109899900.0% in 2019 against a maximum downside of 99.87% in 2019.
  • A 5-year view of Shares Outstanding shows it stood at $11.9 million in 2018, then plummeted by 99.87% to $15000.0 in 2019, then soared by 406.67% to $76000.0 in 2020, then surged by 22153.95% to $16.9 million in 2021, then rose by 3.86% to $17.6 million in 2022.
  • Per Business Quant, the three most recent readings for ANIP's Shares Outstanding are $17.6 million (Q2 2022), $123000.0 (Q1 2022), and $16.9 million (Q4 2021).